A few years ago, Pfizer (PFE +0.51%) looked unstoppable. The company generated more than $100 billion in annual revenue early ...

Pfizer is an innovative pharmaceutical giant that investors have given up on, which is an opportunity if you think long-term.

After years of lagging the market, has Pfizer (NYSE: PFE) finally found a spark? With unimpressive financial results and recent launches that have not generated enough sales to turn things around, the ...

Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer (NYSE: PFE) stock hasn't made for a good investment over the past five years. It has declined by 25% in value over that stretch, while the S&P 500 has climbed by 68%. Investors have lost ...

Pfizer (PFE) stock gained 0.5% premarket after Q1 EPS of $0.75 topped forecasts. Eliquis drove revenue strength as company ...

Pfizer has reached a transition point following declines of some of its biggest blockbusters. The pharma giant is paving the way to growth through new products and acquisitions. 10 stocks we like ...

CHONGQING, CHINA - JANUARY 29: In this photo illustration, a smartphone displays the logo of Pfizer Inc. (NYSE: PFE), an American multinational pharmaceutical company engaged in the development, ...

Pfizer highlighted the performance of a weight-loss drug it acquired in last year's deal to buy Metsera. Pfizer's stock closed 3% lower on Tuesday after investors were disappointed by limited midstage ...